Contineum Therapeutics, Inc. (CTNM) Form 10-Q — Nov 3, 2026
Contineum Therapeutics reported a Q3 2026 net loss of $18.7 million ($0.49 per share) versus $12.8 million a year ago, driven by a $5.0 million jump in R&D spending on the PROPEL-IPF Phase 2 trial of its lead asset PIPE-791. The company ended the quarter with $244.5 million in cash and marketable securities, which management says funds operations for at least 12 months. The filing confirms that J&J's Phase 2 MOONLIGHT-1 trial of partnered PIPE-307 (JNJ-89495120) in major depressive disorder failed to meet its primary efficacy endpoint in September 2026, though the drug was well tolerated.
Key figures
- Revenue
- 0
- Q3 2026 ga
- $5.0 million
- Jnj upfront
- $50.0 million
- Q3 2026 rnd
- $16.0 million
- Nine month rnd
- $40.3 million
- Atm program size
- $100.0 million (amended, exclusive of prior sales)
- Q3 2026 net loss
- $18.7 million
- Interest income q3
- $2.4 million
- Accumulated deficit
- $225.7 million
- Nine month net loss
- $48.3 million
- Atm gross proceeds q3
- $20.0 million at weighted average $14.19 per share
- Jnj milestones potential
- approximately $1.0 billion
- Shares outstanding oct 30 2026
- 39265813
- December 2025 follow on net proceeds
- $93.0 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.